Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 216, Issue 6, Pages 1244-1254Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20182395
Keywords
-
Categories
Funding
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Postdoctoral Research Associate Training Program of the National Institute of General Medical Sciences
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000566] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Since the early 20th century, immunologists have investigated mechanisms that protect vertebrates from damaging immune responses against self-antigens by mature lymphocytes, i.e.,peripheral tolerance. These mechanisms have been increasingly delineated at the molecular level, ultimately culminating in new therapeutics that have revolutionized clinical oncology. Here, we describe basic science and clinical discoveries that converge mainly on two molecules, CTLA-4 and PD-1, that were recognized with the 2018 Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo. We discuss their investigations and those of many others in the field that contravene tolerance through checkpoint inhibition to boost immune killing of malignant cells. We also discuss the mechanisms underlying each therapy, the efficacy achieved, and the complications of therapy. Finally, we hint at research questions for the future that could widen the success of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available